Duane Nash
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Duane Nash
Duane Nash is recorded as CEO at Immunic, Inc. (IMUX). Immunic, Inc. reported in an 8-K filed January 5, 2026 that Duane Nash was appointed Chief Executive Officer and President of Gliomic, effective January 1, 2026.
“On December 29, 2025, in connection with Immunic, Inc.'s (the "Company") recent incorporation of Gliomic Therapeutics Inc., a Delaware corporation, and a wholly-owned subsidiary of the Company ("Gliomic"), Duane Nash, Executive Chairman of the Company, entered into an employment agreement (the "Nash Agreement") with the Company, pursuant to which Dr. Nash will serve as Chief Executive Officer and President of Gliomic, effective January 1, 2026.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2026-01-01–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Immunic, Inc.
Other people whose current roles at this company are on record from its filings.
- Dr. Daniel Vitt CEO
- Duane D. Nash CEO
- Erik Lundgren CEO, Board Member
- Russell J. Cox CEO
- Michael W. Bonney Chairman
- Simona Skerjanec Chairman, Board Member
- Glenn Whaley CFO
- Jason Tardio COO
- Inderpal Singh General Counsel
- Barclay Phillips Board Member
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.